aks-452
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 18, 2021 (NCT04681092)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05124483 | Phase 2 | Dec 1, 2021 | Akston Biosciences Corp, Pharmaceutical Research Associates, Inc. (PRA), TRACER, University of Groningen |
| NCT04681092 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2021 | Akston Biosciences Corp, University of Groningen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akston Biosciences Corp | For profit | 2 | 0 | 1 | 2021 |
| University of Groningen | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2021 |
| TRACER | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1